Biovail

Biovail is a pharmaceutical company that specializes in the development and manufacturing of pharmaceutical drugs. The company was founded in 1983 and is headquartered in Toronto, Canada. Biovail's primary focus is on the development of therapeutic drugs for the treatment of various medical conditions.

History[edit | edit source]

Biovail was established in 1983 by Eugene Melnyk, a Canadian businessman. The company initially focused on the development of generic drugs, but later shifted its focus to the development of innovative pharmaceutical products.

Products[edit | edit source]

Biovail's product portfolio includes drugs for the treatment of cardiovascular diseases, neurological disorders, and pain management. Some of the company's most notable products include Wellbutrin XL, a drug used for the treatment of depression, and Zovirax, an antiviral drug used for the treatment of herpes.

Research and Development[edit | edit source]

Biovail's research and development efforts are focused on the discovery and development of new therapeutic drugs. The company employs a team of scientists and researchers who work in state-of-the-art laboratories to develop new treatments for various medical conditions.

Controversies[edit | edit source]

Biovail has been involved in several controversies over the years. In 2008, the company was fined $10 million by the U.S. Securities and Exchange Commission for accounting fraud. The company was also involved in a lawsuit with Teva Pharmaceuticals over the rights to a generic version of Wellbutrin XL.